Key Takeaways QDEL signed a long-term supply pact with Lifotronic to expand its global immunoassay portfolio.Deal adds 25 new assays and access to 70-test menu across low- to high-throughput platforms.QuidelOrtho reported Q4 2025 revenues of $723.6M, up 2.2%, with EPS of 46 cents.QuidelOrtho (QDEL) recently entered a long-term strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio across select international markets. The deal gives the company access to multiple ana ...